Posted by Nicole Kennedy on Apr 17th, 2024
Amgen (NASDAQ:AMGN – Get Free Report) had its price objective dropped by TD Cowen from $370.00 to $360.00 in a research note issued on Wednesday, Benzinga reports. The firm currently has a “buy” rating on the medical...
More of this article »